MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Begins Phase 2 Clinical Trial Evaluating CBN in the EB Treatment

 InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has started its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of epidermolysis bullosa (“EB”). According to the company, this is the first time cannabinol has advanced to a Phase 2 clinical trial to be studied as a therapeutic option to treat a disease. The study will be conducted in seven different countries at 11 sites; the countries include Austria, Germany, Greece, France, Italy, Israel and Serbia. The company has filed clinical trial applications in all seven countries and has received approval from Austria, France, Greece and Israel, with the first site initiation visit being completed at a clinical site in Austria. Screening for eligible participants is set to begin in Austria soon. INM-755 is a cannabinol cream being considered as a topical therapy to treat EB and potentially other dermatological diseases. Currently EB has very few treatment options. “The achievement of this important milestone along the continuum of pharmaceutical drug development in EB supports our belief that this class of compounds hold broad therapeutic potential,” said InMed president and CEO Eric A. Adams in the press release. “This study further demonstrates InMed’s leadership in the development of rare cannabinoids as therapeutic products. In addition, we look forward to achieving key milestones of our second CBN drug candidate for the treatment of glaucoma in the year ahead.”

To view the full press releases, visit https://ibn.fm/ZlNjl

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”); the company is developing IntegraSyn(TM) to produce pharmaceutical-grade cannabinoids. INM is dedicated to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based medicines. For more information, please visit www.InMedPharma.com.  

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – AmpliTech Group Inc. (NASDAQ: AMPG) Making Strategic Investments to Tap into Hyper-Growth Opportunities

 AmpliTech Group (NASDAQ: AMPG), a company with a rich history in the design and manufacture of microwave amplifiers and components, has always focused on building a strong reputation anchored on performance and quality. This focus has earned it follow-on orders for its Low Noise Amplifier (“LNA”) technology from several global customers, including a high-speed satellite broadband services provider and a Fortune 500 defense and aerospace customer. AmpliTech has also gained recognition through receipt of numerous supplier quality awards, including one for best technology from an industry leading trade magazine. The company anticipates growing business activity and increased customer demand as the economy reopens. A recent article reads, “According to [CEO Fawad] Maqbool, the company is making strategic investments in product development, sales and marketing, and personnel and infrastructure to better position AmpliTech for hyper-growth opportunities seen across several markets, including the build-out of true 5G infrastructure, quantum computing, space exploration and satellite communications (‘SATCOM’).”

To view the full article, visit https://ibn.fm/QFnJW

About AmpliTech Group Inc.

AmpliTech Group designs, develops and manufactures state-of-the-art radio frequency (“RF”) components for global satellite communications, telecom (5G & IoT), space, defense, and quantum computing markets as well as provides systems and component design consulting services. AmpliTech has a 13+ year track record of developing high performance, custom solutions to meet the unique needs of some of the largest companies in the global industries it serves. The company is proud of the unique skills, experience and dedication of its focused team, which enables AmpliTech to deliver superior solutions, faster time to market, competitive pricing and excellent customer satisfaction and repeat business. For more information about the company, visit www.AmpliTechinc.com.

NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Save Foods Inc.’s (NASDAQ: SVFD) Proprietary Technology Designed to Deliver Freshness and Quality, Field to Fork

 Save Foods (NASDAQ: SVFD) is dedicated to delivering integrated solutions for improved safety, freshness and quality every step of the way from field to fork. Speaking as a guest on the latest episode of The Stock2Me Podcase, newly appointed board chairman Dr. Art Dawson noted that Save Foods has successfully completed the development and has also begun to market natural, eco-friendly treatment for fresh produce. These solutions are used in the process of protecting fresh fruits and vegetables, and, therefore, they’re an important part of the economic scheme of the fresh produce value chain. Save Foods’ solution not only prolongs the shelf life of produce, thus reducing wasted food, but it also ensures safe, natural and healthy produce while leaving behind no unhealthy chemical residues. “So, with these innovations in play, Save Foods is addressing one of the biggest issues in the food business today… pathogens. These pathogens are the main cause of food decay and food safety issues… which lead to food waste, human illness and produce recalls,” a recent article quotes Dr. Dawson as saying. “Save Foods offers the first green product with potential to replace the different residual chemicals used today while also addressing the challenges of both food waste and food safety.”

To view the full article, visit https://ibn.fm/wjRoq

About Save Foods Inc.

Save Foods is an innovative, dynamic company addressing two of the most significant challenges in the agri-food-tech industry: food waste and loss and food safety. The company is dedicated to delivering integrated solutions for improved safety, freshness and quality, every step of the way from field to fork. Collaborating closely with its customers, Save Foods develops new solutions that benefit the entire supply chain and improve the safety and quality of life of both workers and the consumers alike. SVFD’s initial applications are in post-harvest treatments in fruit and vegetable packing houses processing, including citrus fruits, avocado, mango, pears, apples and bell pepper. By controlling and preventing pathogen contamination and significantly reducing the use of hazardous chemicals and their residues, Save Foods products not only prolong fresh produce shelf life and reduce food loss and waste, they also ensure a safe, natural and healthy product. For more information about the company, visit www.SaveFoods.co.

NOTE TO INVESTORS: The latest news and updates relating to SVFD are available in the company’s newsroom at https://ibn.fm/SVFD     

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Versatile DehydraTECH(TM) Technology Improving Taste, Bioabsorption, Efficacy of Drugs

 

• Lexaria Bioscience is the global innovator behind the disruptive DehydraTECH(TM) drug delivery technology
• DehydraTECH’s taste-masking capabilities eliminate the need for unwanted sweeteners or chemical masking agents
• The technology also significantly increases the bioavailability of drugs, speeds up the rate of drug onset, and boosts brain absorption
• DehydraTECH presents numerous opportunities and has been evaluated in R&D programs featuring DehydraTECH-processed nicotine, antivirals, and cannabidiol 

Oral delivery is the easiest and most convenient way to administer medications, yet it is prevalently associated with patient noncompliance owing to many drugs’ bitter taste. The problem appears widespread and necessitating remedial bitterness-masking interventions. But as recently as 2013 (relative to the mid-19th century origin of the modern pharmaceutical industry), the taste-masking of oral solid dosage forms was still a major challenge that needed to be addressed by formulation or pharmaceutical scientists (https://ibn.fm/7wmaW).

The most commonly used taste-masking methods at that time were film coating and the use of sweeteners, sugars, or flavors, but the latter is considered ineffective due to its inability to adequately mask the bitter taste. Still, less conventional methods such as microencapsulation, spray drying, supercritical fluids, and more had already been reported as successful taste-masking techniques. 

Since then, Lexaria Bioscience (NASDAQ: LEXX), a global innovator whose patented DehydraTECH(TM) drug delivery technology could potentially improve oral administration of Active Pharmaceutical Ingredients (“APIs”), has led the pharmaceutical industry in advancing novel taste-masking techniques.

With part of its R&D having progressed from animal studies to human clinical studies, the company has so far established that DehydraTECH masks unwanted taste, thereby eliminating the need for sugar-filled edibles; improves the speed of drug onset; increases the effectiveness of drug delivery into the bloodstream (bioavailability); and boosts brain absorption (https://ibn.fm/la1J9). 

DehydraTECH’s taste-masking capabilities result from the use of fatty acids. The technology combines the API with fatty acids, such as long-chain fatty acid (“LCFA”), before applying the resultant compound to food/carrier particles (substrate material), performing dehydration synthesis procedure, and, finally, rendering it as powder or liquid for use in desired final form factor. Importantly, according to an evaluation LEXX conducted in collaboration with National Research Council, the largest R&D organization in Canada, DehydraTECH does not alter the chemical structure of the API.

The fatty acids offer dual benefits. First, they are believed to block and divert bound APIs away from bitter taste receptors, essentially rendering them flavorless, as well as odorless. “DehydraTECH formulations do not require unwanted sweeteners or chemical masking agents for flavor and odor blocking, allowing manufacturers to create low-sugar products with fewer calories, while also avoiding the use of excessive artificial sweeteners,” reads the company’s website (https://ibn.fm/TfY0x).

The LCFA also promotes quick absorption into lymphatics, bypassing the first-pass liver effect, which drastically reduces the bioavailability or overall effectiveness of orally ingested drugs. In this regard and based on findings of clinical testing, DehydraTECH significantly increases bioavailability for fat-soluble drugs.

DehydraTECH has so far been evaluated as part of nicotine, antivirals, and cannabinoids (“CBD”) R&D programs. The nicotine program showed that the drug delivery platform significantly increased the quantity of nicotine delivered. It was also responsible for 295% higher brain levels of nicotine compared to controls. 

Additionally, its first 2021 human clinical study under the CBD program, HYPER-H21-1, has evidenced a rapid and sustained decline in blood pressure, with the reduction being more pronounced in the first 10 to 50 minutes of the study. The second 2021 human clinical study, HYPER-H21-2, has demonstrated up to 23% drop in blood pressure with DehydraTECH-CBD compared with placebo. Though Lexaria still awaits additional analyses, its drug delivery technology has proven useful for potentially treating hypertension.

Thirdly, its antiviral program, featuring cell-based and animal studies using Remdesivir and antiviral drugs being investigated for SARS-CoV-2 and HIV/AIDS, has demonstrated enhanced drug delivery.

Since it began developing DehydraTECH in 2014, Lexaria has significantly strengthened and broadened the technology to an unprecedented degree. Even so, more may still be in the offing for the company currently disrupting the pharmaceutical industry.

For more information, visit the company’s website at www.LexariaBioscience.com. 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Communications Tech and Data Services Provider FingerMotion Inc. (FNGR) Building Strong IP in China’s Large Insurance Market

 

• FingerMotion Inc., has become a provider for China’s booming e-commerce market with rich communication services (“RCS”) and big-data insights, developing its Sapientus database as a solution for clients’ predictive services needs
• In addition to its SMS, MMS and mobile top-up business, FingerMotion’s focus on adapting Sapientus to the needs of the insurance industry are driving revenues to new records each quarter
• In China, insurance is compulsory to protect certain societal needs, such as pensions, medical care, employment (and unemployment), and maternity care, creating a ready market for insurance providers
• The Sapientus platform creates proprietary matrices for assessing consumer risk potential using context-based outlooks in accordance with established behaviors

The development of business capabilities to harvest and apply big data insights is affecting revenue streams that vary in size and impact from national government contractors (https://ibn.fm/yE6s6) to farmers harvesting their fields (https://ibn.fm/Vqw3t). 

Industry e-magazine Datamation reported Sept. 26 on Splunk findings that “organizations with ‘mature data practices’ release twice as many products and increase employee productivity at double the rate of organizations with less mature data practices” (https://ibn.fm/kQuHI). 

Big data communications technology innovator FingerMotion (OTCQX: FNGR) is focusing its new platform on China’s insurance market as the nation serving as the home to some 1.4 billion people continues to build a powerful economy on the efforts of factories crucial to the global supply chain. 

FingerMotion launched its Big Data Insights division with its flagship database IP Sapientus last year and attracted global insurance behemoth Pacific Life Re-insurance as a client interested in developing a customer base within China. 

Sapientus is a stand-out technology that applies publicly available data to clients’ risk forecast needs, generating proprietary matrices that assimilate information on individuals’ behaviors to create context-based outlooks for customers. 

It’s a service that’s particularly attractive in China since the country’s credit and insurance risk standards are still in a developmental stage and Sapientus can help provide an alternative means of judging potential liabilities for a corporate client. 

During the past year, FingerMotion’s revenues have seen steady growth, largely due to mobile communications services, and the Pacific Life agreement earlier this year positioned it for an even more promising future.  CEO Martin Shen said during a corporate update conference call discussing the company’s first-quarter financial results in August that FingerMotion’s top-up business had risen 341 percent and mobile SMS and MMS services had increased by 77 percent, and that “some significant funds” raised after the quarter ended will likely lead to a higher outcome on the balance sheet once the Q2 report is completed. 

“Most of the e-commerce companies operate in the red for quite a while before they turn a profit, but our current trajectory has us moving in that profitable direction a bit quicker than maybe other companies have been,” Shen said (https://ibn.fm/OPdc3).

Shen acknowledged that the company has considered eventually focusing its big data platform on other industries beyond insurance and in markets beyond China’s borders, but said the company needs to stay focused on its immediate purpose before expanding its reach. 

“We’ve always thought of the ability of the algorithms that we have. It’s not really just to perfect those algorithms but it’s also to have them exportable and replicated in other jurisdictions, in other markets. … But again, that takes time to develop, and we’re really still developing what we’re doing right now in China,” Shen said. “Right now, let’s just build and make sure that our foundation is strong first.”

For more information, visit the company’s website at www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR 

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Group of Patients in Potentially Pivotal Trial

 CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced the dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types of brain cancer. According to the update, further patient enrollment, randomization and dosing is currently underway as well as a robust lineup of globally located clinical sites, which are advancing toward activation and enrollment. “As one of the most aggressive, deadly and treatment-resistant cancers that forms in the brain where current standard of care remains ineffective in ~60% of patients, the treatment landscape for GBM is in desperate need of a better treatment option. We continue to be encouraged by the data seen from Berubicin to date and are excited to now have patient dosing underway in this potentially pivotal trial. Our team is committed to expeditiously advancing the study and looks forward to further understanding the full potential of Berubicin to offer improvement and overall survival in this devastating disease,” said Erin Dunbar, M.D., founding physician of the Brain Tumor Center and director of neuro-oncology at Piedmont Atlanta Hospital, and principal investigator for the study.

To view the full press release, visit https://ibn.fm/I38Ze

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) Releases Pricing of Proposed Public Offering

 Kaival Brands (NASDAQ: KAVL), the exclusive global distributor of products by Bidi(R) Vapor LLC, has announced an underwritten public offering of 4,700,000 shares of its common stock and accompanying warrants. According to the announcement, the pricing of the public offering, which included each share of common stock being sold together with 0.75 warrants for a combined price of $1.70, is $8 million before deducting typical underwriting discounts and offering expenses. The company anticipates using net proceeds from the offering to fund working capital and general corporate purposes. KAVL anticipates granting the underwriters a 45-day option to purchase up to an additional 15% of the number of shares offered, or 705,000 shares of common stock and/or warrants to purchase 528,750 shares of common stock to cover over-allotments at the public offering price.

To view the full press releases, visit https://ibn.fm/Z6cO2 and https://ibn.fm/Jdh0Y

About Kaival Brands Innovations Group Inc.

Based in Grant, Florida, Kaival Brands is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. The company’s vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. Kaival Brands is the exclusive global distributor of all products manufactured by Bidi Vapor. For more information about the company, visit www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html